go-v.orgdoi

Endocrine resistance: mechanisms and therapeutic targets

Senthil Damodaran, Sarmila Majumder, Bhuvaneswari Ramaswamy · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.49
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

Endocrine therapy remains the cornerstone in the effective management of estrogen receptor-positive breast cancers. Since the introduction of tamoxifen, the first therapy to target estrogen receptor, several agents have been approved to block the estrogen-mediated signaling in breast cancer management. However, successful clinical outcomes are hindered by the alternate survival mechanisms either innately active or developed by the cancer cell over time. Identifying these signaling pathways at the outset or over the treatment period, and developing targeted therapies to inhibit these pathways, would be crucial to improve clinical outcomes.

This article reviews the landscape of the resistant pathways identified so far and the translational work that aims to target these pathways to enhance the effectiveness of endocrine therapy.

Open the resolved locator · 10.4155/cli.13.49

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:31 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.49
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.